| Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer S Van de Ven, V Smit, TJA Dekker, JWR Nortier, JR Kroep Cancer treatment reviews 37 (6), 422-430, 2011 | 264 | 2011 |
| First-line chemotherapy for malignant peripheral nerve sheath tumor (MPNST) versus other histological soft tissue sarcoma subtypes and as a prognostic factor for MPNST: an … JR Kroep, M Ouali, H Gelderblom, A Le Cesne, TJA Dekker, ... Annals of oncology 22 (1), 207-214, 2011 | 255 | 2011 |
| Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-β signalling FF Zhou, Y Drabsch, TJA Dekker, AG De Vinuesa, Y Li, LJAC Hawinkels, ... Nature communications 5 (1), 3388, 2014 | 205 | 2014 |
| Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial … TJA Dekker, CJH Van De Velde, GW Van Pelt, JR Kroep, JP Julien, ... Breast cancer research and treatment 139, 371-379, 2013 | 180 | 2013 |
| Advanced melanoma: current treatment options, biomarkers, and future perspectives EA Rozeman, TJA Dekker, JBAG Haanen, CU Blank American Journal of Clinical Dermatology 19 (3), 303-317, 2018 | 120 | 2018 |
| The prognostic role of TGF-β signaling pathway in breast cancer patients EM De Kruijf, TJA Dekker, L Hawinkels, H Putter, V Smit, JR Kroep, ... Annals of oncology 24 (2), 384-390, 2013 | 101 | 2013 |
| The prognostic value of tumour–stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review CJH Kramer, KMH Vangangelt, GW Van Pelt, TJA Dekker, R Tollenaar, ... Breast cancer research and treatment 173, 55-64, 2019 | 98 | 2019 |
| Multicenter matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI) identifies proteomic differences in breast-cancer-associated stroma TJA Dekker, BD Balluff, EA Jones, CD Schöne, M Schmitt, M Aubele, ... Journal of proteome research 13 (11), 4730-4738, 2014 | 88 | 2014 |
| Reliability of core needle biopsy for determining ER and HER2 status in breast cancer TJA Dekker, V Smit, GKJ Hooijer, MJ Van de Vijver, WE Mesker, ... Annals of oncology 24 (4), 931-937, 2013 | 87 | 2013 |
| Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach TJA Dekker, ST Borg, GKJ Hooijer, SL Meijer, J Wesseling, JE Boers, ... Breast cancer research 14, 1-12, 2012 | 70 | 2012 |
| The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study T Roeke, M Sobral-Leite, TJA Dekker, J Wesseling, VT Smit, ... Breast cancer research and treatment 166, 435-445, 2017 | 65 | 2017 |
| The prognostic value of tumor–stroma ratio in tumor‐positive axillary lymph nodes of breast cancer patients KMH Vangangelt, LSA Tollenaar, GW van Pelt, EM de Kruijf, TJA Dekker, ... International journal of cancer 143 (12), 3194-3200, 2018 | 46 | 2018 |
| Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial TJA Dekker, A Charehbili, V Smit, P ten Dijke, EMK Kranenbarg, ... Molecular oncology 9 (6), 1120-1128, 2015 | 46 | 2015 |
| Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer SC Hagenaars, S de Groot, D Cohen, TJA Dekker, A Charehbili, ... International journal of cancer 149 (5), 1181-1188, 2021 | 45* | 2021 |
| Proteomic serum biomarkers and their potential application in cancer screening programs A Huijbers, B Velstra, TJA Dekker, WE Mesker, YEM van der Burgt, ... International journal of molecular sciences 11 (11), 4175-4193, 2010 | 43 | 2010 |
| Towards imaging metabolic pathways in tissues TJA Dekker, EA Jones, WE Corver, RJM van Zeijl, AM Deelder, ... Analytical and bioanalytical chemistry 407, 2167-2176, 2015 | 35 | 2015 |
| Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach TJA Dekker, S Ter Borg, GKJ Hooijer, SL Meijer, J Wesseling, JE Boers, ... Breast cancer research and treatment 152, 247-252, 2015 | 29 | 2015 |
| Quantitative assessment of lymph vascular space invasion (LVSI) provides important prognostic information in node-negative breast cancer TJA Dekker, CJH Van de Velde, D Van Bruggen, WE Mesker, ... Annals of oncology 24 (12), 2994-2998, 2013 | 18 | 2013 |
| Tirzepatide Once Weekly for the Treatment of Obesity. TJA Dekker The New England journal of medicine 387 (15), 1433-1433, 2022 | 15 | 2022 |
| Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer RF van Golen, TJA Dekker The Lancet Oncology 21 (11), e515, 2020 | 11 | 2020 |